English

Invitation to audiocast for Devyser’s Q2 Report 2022

Report this content

On Wednesday August 24, at 09.00 CET, Devyser Diagnostics AB will host an online presentation of its Q2 2022 interim report (which will have been published earlier on August 24, at 08.00 CET). The presentation will be held in English. 

 

The dial-in numbers for the conference call are:  

 

Sweden: +46-8-5051-6386

USA: +1-412-317-6300

Rest of the world: +44-20-319-84884

 

PIN cod for the teleconference: 2420061#

 

The presentation will be webcast and can be accessed from the following web address: 

https://tv.streamfabriken.com/devyser-diagnostics-q2-2022

 

Speakers: CEO Fredrik Alpsten, CFO Sabina Berlin and founder and Deputy CEO Ulf Klangby

 

 

For more information, please contact:

Fredrik Alpsten, CEO
E-mail: fredrik.alpsten@devyser.com
Tel: +46 706 673 106


Sabina Berlin, CFO
E-mail: sabina.berlin@devyser.com
Tel: +46 739 519 502

 

About Devyser Diagnostics AB (publ)

Devyser develops, produces, and commercializes genetic test kits for laboratories in more than 45 countries. The products are used for advanced DNA testing within hereditary diseases, oncology, and transplantation to guide targeted cancer therapies, diagnose a wide array of genetic diseases, and to assist in post-transplant follow-up. Devyser’s products simplify genetic testing processes, minimize hands-on time and deliver rapid, accurate, and trusted results. Devyser was founded in 2004 and is based in Stockholm, Sweden.

Devyser’s shares are listed on Nasdaq First North Growth Market (ticker: DVYSR). The company’s certified adviser is Redeye AB. For more information, please visit www.devyser.com.

 

The information was submitted for publication, through the agency of the contact persons above, on August 17, 2022 at 11:00 CET.

Subscribe